Medacta Group SA (MOVE) AI Stock Analysis

• Market Cap: $2.78B
• Dividend Yield: 0.37%
• Average Volume (3M): 13.68K
• Price to Earnings (P/E): 39.9
• Beta (1Y): 1.15
• Revenue Growth: 13.35%
• EPS Growth: 50.65%
• Country: CH
• Employees: 1,907
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Devices
• EPS (TTM): 1.65
• Shares Outstanding: 20,000,000
• 10 Day Avg. Volume: 12,912
• 30 Day Avg. Volume: 13,681
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $149.34
• Price Target Upside: 7.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Medacta Group SA shows strong financial performance with robust revenue growth and profitability. However, the stock is trading below key technical levels, indicating bearish sentiment. Additionally, the valuation appears stretched with a high P/E ratio and low dividend yield. While financial health is a strong point, technical and valuation concerns weigh on the overall score.

Positive Factors

Financial Performance

Medacta released full fiscal year results that delivered a ~4% beat on Adjusted EBITDA, indicating strong financial performance.

Growth Strategy

Medacta outlined a comprehensive growth strategy at their first CMD that hits the right notes around the current product opportunity set, execution and deliverable targets, and capital deployment.

Negative Factors

Capital Expenditure

Operational free cash flow increased by 42%, indicating strong cash flow generation, even as capital expenditure rose, showing client traction in new product lines.

Medacta Group SA Business Overview & Revenue Model

Company Description

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

How the Company Makes Money

Medacta Group SA generates revenue by designing and selling orthopedic implants and surgical instruments primarily for hip, knee, shoulder, and spine surgeries. The company's key revenue streams include direct sales to hospitals and healthcare providers, as well as partnerships with medical distributors and suppliers across various regions. Medacta also invests in surgeon training and education programs, which help to increase the adoption of its products. Additionally, the company benefits from ongoing research and development to innovate new solutions that cater to the evolving needs of the healthcare sector, thereby maintaining a competitive edge in the market.

Medacta Group SA Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
510.78M	437.12M	363.13M	302.49M	310.62M
	Gross Profit
347.85M	305.26M	261.25M	214.26M	223.70M
	EBIT
74.44M	69.46M	67.08M	52.84M	40.09M
	EBITDA
119.64M	106.96M	97.81M	81.96M	66.50M
	Net Income Common Stockholders
47.36M	46.25M	51.52M	37.09M	11.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.79M	32.26M	20.40M	48.07M	27.24M
	Total Assets
695.87M	584.49M	489.27M	441.94M	412.56M
	Total Debt
201.98M	170.25M	132.66M	150.00M	152.15M
	Net Debt
181.19M	137.99M	112.26M	101.93M	124.91M
	Total Liabilities
365.83M	309.83M	262.87M	277.22M	289.33M
	Stockholders Equity
330.04M	274.65M	226.40M	164.72M	123.23M
Cash Flow		Free Cash Flow
-7.09M	10.35M	7.57M	32.31M	1.16M
	Operating Cash Flow
75.13M	73.51M	54.06M	59.59M	42.63M
	Investing Cash Flow
-80.61M	-65.11M	-52.04M	-34.19M	-42.04M
	Financing Cash Flow
-10.13M	3.44M	-31.21M	-6.03M	-10.98M

Medacta Group SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 139.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Positive. The current price of 139 is above the 20-day moving average (MA) of 128.04, above the 50-day MA of 127.30, and above the 200-day MA of 120.90, indicating a bullish trend. The MACD of 3.93 indicates Negative momentum. The RSI at 63.80 is Neutral, neither overbought nor oversold. The STOCH value of 69.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOVE.

Medacta Group SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STMN	73 Outperform	CHF17.04B	44.08		0.90%	3.82%	57.08%
MOVE	61 Neutral	$2.78B	39.87	20.81%	0.37%	13.35%	50.65%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.53%

Medacta Group SA Corporate Events

Medacta Group SA Approves Board Proposals and Financial Strategies at AGM

Medacta Group SA announced that all proposals by the Board of Directors were approved at the Annual General Meeting, including a distribution of CHF 13.7 million to shareholders and the re-election of key board members. The AGM, attended by 89.41% of the share capital, also saw the approval of various financial and remuneration reports, reinforcing Medacta’s stable governance and financial strategies.

Medacta Announces 2025 AGM Details and Key Proposals

Medacta Group SA has announced the details of its 2025 Annual General Meeting, scheduled for May 7, 2025, in Rancate, Switzerland. Shareholders can attend in person or vote via proxy, and are invited to submit questions to the Board of Directors. Key proposals include a dividend distribution of CHF 13.7 million, the re-election of Dr. Alberto Siccardi as Chairman, and the re-election of board members and the Remuneration Committee. The meeting will also address the approval of compensations for the Board and Executive Management, and the re-election of the Independent Proxy Holder and Auditors.

Medacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic Solutions

Medacta Group SA reported a strong financial performance for 2024, with revenue increasing by 16.2% in constant currency to Euro 590.6 million and an adjusted EBITDA margin of 28.0%. The company attributes its success to innovative product launches, such as the GMK SpheriKA knee implant and the NextAR Rod Optimizer, which enhance surgical planning and patient outcomes. Medacta’s expansion efforts, including facility enlargements and workforce growth, aim to meet rising demand and support future growth. The company anticipates continued revenue growth in 2025, driven by its commitment to cutting-edge technologies and personalized medical solutions.